USANA Health Sciences, Inc. (NYSE:USNA) Holdings Raised by Northern Trust Corp

Northern Trust Corp grew its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 16.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 135,937 shares of the company's stock after acquiring an additional 19,266 shares during the quarter. Northern Trust Corp owned approximately 0.71% of USANA Health Sciences worth $4,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in USNA. Exchange Traded Concepts LLC increased its holdings in shares of USANA Health Sciences by 11.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company's stock valued at $308,000 after acquiring an additional 869 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of USANA Health Sciences by 8.8% in the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock valued at $21,247,000 after acquiring an additional 47,745 shares during the last quarter. R Squared Ltd bought a new stake in shares of USANA Health Sciences in the 4th quarter valued at approximately $28,000. Rhumbline Advisers grew its stake in USANA Health Sciences by 39.8% during the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock worth $1,773,000 after buying an additional 14,068 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock worth $1,924,000 after buying an additional 1,480 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Jim Brown sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares of the company's stock, valued at $463,150.52. This trade represents a 24.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO G Doug Iiekking sold 4,548 shares of the firm's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $29.61, for a total value of $134,666.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,142 shares of company stock worth $655,050. 0.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

USNA has been the subject of a number of recent research reports. Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday. Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. Finally, DA Davidson lowered their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th.

USANA Health Sciences Trading Down 2.1%

USNA traded down $0.64 during trading on Friday, reaching $29.42. 125,464 shares of the company were exchanged, compared to its average volume of 132,580. USANA Health Sciences, Inc. has a 52 week low of $23.10 and a 52 week high of $49.16. The firm has a 50 day moving average of $27.11 and a 200 day moving average of $32.19. The stock has a market cap of $547.89 million, a P/E ratio of 10.40, a PEG ratio of 0.93 and a beta of 0.60.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.70 by $0.03. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $249.54 million during the quarter, compared to analyst estimates of $243.08 million. During the same quarter in the previous year, the firm posted $0.86 EPS. As a group, analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.